Prodrugs and patents: Enhancing therapy adherence and reducing side effects
As the approval date for Bristol Myers Squibb’s (BMS) schizophrenia drug KarXT (xanomeline-trospium) fast approaches, the schizophrenia field eagerly anticipates…
As the approval date for Bristol Myers Squibb’s (BMS) schizophrenia drug KarXT (xanomeline-trospium) fast approaches, the schizophrenia field eagerly anticipates…
Athira Pharma has released topline data from the Phase II/III LIFT-AD trial of its lead Alzheimer’s disease therapy, fosgonimeton. The…
The US Food and Drug Administration (FDA) has granted an orphan drug designation to Actimed Therapeutics’ S-oxprenolol (ACM-002) for the…
On 6 August, at the International Association for the Study of Pain (IASP) World Congress, an oral presentation held during…
Biopharmaceutical company UCB has entered a divestment agreement in China to sell, divest and license its mature neurology and allergy…
Jazz Pharmaceuticals’ efforts to get its cannabidiol therapy approved in Japan have hit a snag after a Phase III trial…
Organon and Eli Lilly and Company have broadened their commercial agreement under which the former will be the sole distributor…
The Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved the use of BioArctic and Eisai’s…
Lykos Therapeutics’ midomafetamine (MDMA) treatment for post-traumatic stress disorder (PTSD) has suffered another setback after the US Food and Drug…
The US Food and Drug Administration (FDA) has approved Servier's VORANIGO for patients aged 12 years and above with Grade…